IDH2 and central nervous system cancer: We discuss preclinical breakthroughs that have led up to our current understanding of IDH in the pathogenesis of IDH-mutant glioma, progress in the development of IDH inhibitors, and studies evaluating the use, safety, and efficacy of various IDH inhibitors.